Linesight has announced the addition of two senior executives to the leadership team in order to expand the company’s global footprint and address growing customer needs in the Life Sciences space. Jeff Peragallo has joined as Director of Life Sciences, USA while Nigel Barnes takes on the role of Director of Life Sciences, EMEA. Peragallo will be based in New York and Barnes in London.
Gerard Campbell, Group CEO at Linesight said,
“The appointments of Jeff and Nigel are strategic additions to our Life Sciences management team as we continue to build on successes in this sector in a variety of regions across the globe. We are proud to have been able to attract such heavy hitters from the industry to Linesight. Both Jeff and Nigel have strong technical, commercial and industry knowledge, which will benefit our clients and partners, and their design and implementation teams in maximizing value.”
Prior to joining Linesight, Jeff Peragallo spent over five years as Vice President at Hill International, driving revenue growth in its Life Sciences division. He previously spent fifteen years in global procurement roles at Merck, in its capital sourcing organization. Jeff brings a unique blend of technical knowledge and commercial Life Sciences experience, to help Linesight’s clients deliver their large, complex construction projects as efficiently as possible.
Jeff will be attending the upcoming CURT conference in Orlando on 11-13 February.
Prior to joining Linesight, Nigel Barnes spent over twenty two years as Vice President of Engineering for GlaxoSmithKline and eight years as Head of Industry for WSP in capital project delivery programs. He also spent over two years as Managing Director of IPS (Integrated Project Services). Nigel’s role will be to support Linesight’s clients in making the appropriate CAPEX investments across their portfolio of Life Sciences assets, as well as working closely with them to manage the design and build teams to ensure efficient and successful outcomes.
Linesight is rapidly expanding its Life Sciences business globally and has a strategic imperative to respond to the needs of its local and multinational clients. The company is involved in a number of exciting complex construction projects across multiple sub-sectors of the industry, including Pharmaceutical, Bio-Technology and MedTech.
Fiona D’Arcy, D’Arcy Marketing
O: +353 1 2354776
M: +353 87 2808828